Innate Killer Summit 2018 presents cutting-edge innovations and the latest clinical data for NK cell therapies

Akron Biotech was proud to be a sponsor of this year’s Innate Killer Summit held in San Diego, California. The Innate Killer Summit is the leading, dedicated end-to-end meeting serving as a catalyst to ensure successful clinical and commercial translation of NK cell immunotherapies. The most current and advanced clinical data was presented as well

Improving tumor recognition and elimination by NK cells with engineered antibodies

Current immunotherapies for the treatment of cancer exploit engineered T cells, a lymphocyte of the adaptive immune system. An alternative avenue is utilizing the major players of the innate immune system — natural killer (NK) cells. NK cells are innate lymphocytes that express activating receptors, including the NK group 2D (NKG2D) receptor. These NKG2D receptors

First allogeneic stem cell therapy approved in Europe

TiGenix and Takeda announced that the European Commission (EC) has approved Alofisel (darvadstrocel) for the treatment of complex perianal fistulas in adult patients with nonactive/mildly active luminal Crohn’s disease, marking the first allogeneic stem cell therapy to receive central marketing authorization approval in Europe. Crohn’s disease is a chronic condition that causes intestinal inflammation. A

Slow release of immunotherapy after surgery prevents tumor recurrence and metastases

With the FDA approval of Kymriah to treat B-cell acute lymphoblastic leukemia and Yescarta to treat B-cell lymphoma, immunotherapy for cancer is becoming increasingly common. These existing therapies are systemically delivered and are not necessarily tumor-specific. This systemic administration can have major side effects by stimulating the activity of the entire immune system, not just

Synthetic IL-2 cytokine-receptor pairs enable selective targeting of engineered T cells

Interleukin-2 (IL-2) is a cytokine critical to effector T cell expansion, survival, and function. Importantly, IL-2 is supplemented in the production of T cells for immunotherapy, including CAR-T cell therapies. While IL-2 can improve T cell survival and efficacy, IL-2 provokes a wide range of responses by simultaneously activating and repressing different components of the

Patient-derived cancer organoids model patients’ clinical drug responses

Organoids are 3D in vitro cell cultures that represent simplified versions of an organ that capture the key architecture, functionality, and genetic features of original tissues. Patient-derived cancer organoids are one variation that can be derived from primary patient tumors and studied in the laboratory. These patient-derived organoids (PDOs) have served as preclinical models of

Akron CEO Zylberberg interviewed for the Innate Killer Summit 2018

The Innate Killer Summit is the leading, dedicated end-to-end meeting serving as the catalyst to ensure successful clinical and commercial translation of Natural Killer (NK) cell immunotherapies. Leading up to the March 2018 event in San Diego, CA, Akron Biotechnology CEO Claudia Zylberberg, Ph.D. shared some key issues and questions arising in the NK therapy